Extract to table

This memorandum shall not be disclosed, distributed, or shared with any person or entity, in whole or in part, without the prior written approval of Calderwood & Harkness LLP

2(b), which requires that since the date of the Agreement, no Material Adverse Effect shall have occurred

Veridian's argument implicitly assumes that Penterra must wait for final trial data before asserting an MAE, but this is not the law

The partial clinical hold must be assessed not in isolation but in conjunction with the Marlowe Asset Management-2 clinical data

12, which provides, in relevant part, that the parties acknowledge that irreparable damage would occur if any provision of the Agreement were not performed in accordance with its terms and that the parties shall be entitled to seek specific performance to enforce the terms and provisions of the Agreement